Does Iron Affect Macular Degeneration?

Does Iron Affect Macular Degeneration?

Iron does affect macular degeneration: too little iron impairs normal retinal metabolism, but too much iron promotes oxidative damage, inflammation, and a form of cell death called ferroptosis that may accelerate AMD progression.(1–4) Retinal iron levels rise with age and are higher in AMD eyes than in age‑matched controls, especially in photoreceptors, retinal pigment epithelium (RPE), Bruch’s membrane, and drusen.(1,3,5–7)pmc.ncbi.nlm.nih+5

How Iron Normally Works in the Retina

Iron is essential for phototransduction, mitochondrial energy production, and neurotransmitter metabolism in the retina.(1,5,8) It is transported into retinal cells mainly as transferrin‑bound iron via transferrin receptors, stored in ferritin, and exported by ferroportin with the help of ferroxidases such as ceruloplasmin.(1,5,8)pmc.ncbi.nlm.nih+2

The retina tightly regulates this traffic through iron‑handling proteins and the hormone hepcidin, which down‑regulates ferroportin when iron is abundant to prevent overload.(2,5) When these regulatory systems function well, iron cycles through its normal roles without causing oxidative injury.pmc.ncbi.nlm.nih+1

How Excess Iron May Promote AMD

Oxidative stress and lipid peroxidation

Unbound or poorly liganded iron participates in the Fenton reaction, generating hydroxyl radicals from hydrogen peroxide, which are among the most damaging reactive oxygen species.(1,3,5,8) The macula’s high content of polyunsaturated fatty acids makes it particularly susceptible to iron‑driven lipid peroxidation, leading to membrane damage, mitochondrial dysfunction, and DNA injury in RPE and photoreceptors.(3,4,6)pubmed.ncbi.nlm.nih+5

Histologic studies show that macular iron content approximately doubles with age and is further increased in AMD, with iron deposits in RPE, Bruch’s membrane, and drusen.(3,6,7) This accumulation parallels markers of oxidative stress and supports a mechanistic link between iron overload and degenerative changes in AMD.(3,6,7)pmc.ncbi.nlm.nih+2

Ferroptosis: iron‑dependent cell death

Recent work highlights ferroptosis, a regulated cell‑death pathway driven by iron‑dependent phospholipid peroxidation, as a contributor to RPE loss in AMD.(4,9,10) In cultured RPE cells, oxidative stress combined with elevated iron triggers ferroptotic death characterized by lipid peroxidation, glutathione depletion, and ferrous‑iron accumulation; iron chelators and ferroptosis inhibitors can rescue these cells.(4,9,10)pmc.ncbi.nlm.nih+2

A 2025 review concludes that ferroptosis participates in retinal cell degeneration in AMD and may represent a therapeutic target, for example via iron chelation, upregulation of antioxidant defences, or direct ferroptosis inhibitors.(4,9)pubmed.ncbi.nlm.nih+1

Genetic and regulatory defects

Mouse models with disrupted iron‑regulatory proteins—such as hepcidin or ceruloplasmin/hephaestin deficiency—develop progressive retinal iron overload and photoreceptor/RPE degeneration resembling human AMD.(2,5,8) These findings indicate that when retinal iron‑export pathways fail, iron accumulation alone is enough to drive chronic degeneration.frontiersin+2

What Do Studies Say About Iron Supplements and AMD?

Evidence directly linking oral iron supplements to AMD onset is limited, but there are signals of risk in people who already have neovascular AMD. A secondary analysis of the CATT trial found that oral iron supplement use was associated with a significantly higher risk of retinal or subretinal hemorrhage at baseline in eyes with neovascular AMD, with a dose‑dependent effect and nearly double the risk among hypertensive patients.(11,12)pmc.ncbi.nlm.nih+1

Case reports and small series describe retinal toxicity and degeneration after parenteral iron therapy or severe systemic iron overload (for example hemochromatosis), with iron deposits in retinal vascular endothelium and perivascular tissues.(3,11,13) These observations suggest that unnecessary high‑dose iron may worsen retinal vascular fragility in susceptible AMD eyes, although large prospective trials are lacking.pmc.ncbi.nlm.nih+2

For people without anemia or iron deficiency, experts generally recommend avoiding long‑term high‑dose iron supplementation because total‑body iron stores rise with age and excess iron can amplify oxidative stress implicated in AMD and other neurodegenerative diseases.(1,3,5,8)pmc.ncbi.nlm.nih+3

How Iron-Related Changes Affect Daily Vision

Iron‑driven damage is microscopic, but its outcomes are familiar clinical features of AMD. Progressive oxidative injury and ferroptosis in RPE and photoreceptors contribute to geographic atrophy, leading to central blind spots, difficulty reading, and problems with low‑light or contrast‑rich tasks.(3,4,6) In neovascular AMD, iron‑related toxicity to choroidal and retinal endothelial cells may increase the likelihood of retinal or subretinal hemorrhage, causing sudden vision loss or dense central scotomas.(11,12)pmc.ncbi.nlm.nih+4

Because these changes are cumulative, even modest excess iron over many years may add to other stresses (aging, smoking, genetic risk, complement activation) to push vulnerable maculas toward clinical AMD.

Practical Implications and Risk Mitigation

• Do not self‑prescribe high‑dose iron. People with AMD or at high risk should only take iron supplements if there is a clear medical indication (for example confirmed iron‑deficiency anemia) and under physician supervision.(1,3,11,13)pubmed.ncbi.nlm.nih+3
• Check for anemia before supplementing. Laboratory testing (hemoglobin, ferritin, transferrin saturation) helps ensure iron is necessary and guides dose and duration.
• Discuss supplements with your retina specialist. For patients with neovascular AMD, clinicians may reconsider non‑essential iron supplementation, especially at doses ≥18–36 mg/day and in those with hypertension, given the observed hemorrhage signal.(11,12)reviewofoptometry+1
• Support iron balance indirectly. A balanced diet, avoidance of unnecessary iron‑fortified products if iron‑replete, and management of systemic conditions that affect iron (for example chronic inflammation, liver disease) help maintain physiological levels.(5,8)pmc.ncbi.nlm.nih+1

Investigational strategies—such as local iron chelators, modulation of hepcidin signalling, or ferroptosis inhibitors—are being explored in preclinical AMD models but are not yet available as standard therapy.(4,8,9)pmc.ncbi.nlm.nih+2

When Should Someone Seek Specialist Advice About Iron?

You should speak with your ophthalmologist or retina specialist if you:

• Have AMD and are taking oral iron supplements (with or without a history of anemia).
• Have systemic iron overload conditions (for example hemochromatosis, repeated transfusions) and want to understand retinal risks.
• Experience new retinal or subretinal hemorrhages while on iron therapy.

Coordination between your eye‑care professional and primary‑care or hematology team can balance systemic benefits of iron treatment with potential ocular risks.

FAQs

Does eating iron‑rich foods worsen AMD?
Normal dietary iron intake from foods does not appear to increase AMD risk; the concern is excess, unregulated iron, particularly from high‑dose supplements or systemic iron overload.(1,3,5)pubmed.ncbi.nlm.nih+2

Is low iron (anemia) dangerous for the retina?
Severe anemia can reduce oxygen delivery and may cause retinal hemorrhages, but treating true iron‑deficiency anemia is important for overall health and is not contraindicated in AMD when carefully monitored.(3,11)pmc.ncbi.nlm.nih+1

Are iron chelators used to treat AMD today?
Not yet. Iron chelators and ferroptosis inhibitors show protective effects in RPE and animal models, but clinical trials in AMD are still at an early stage.(4,9,10)sciencedirect+2

Should all AMD patients be screened for iron overload?
Routine extensive iron‑overload screening is not standard, but basic labs (for example ferritin, transferrin saturation) may be reasonable in patients with AMD who have risk factors such as family history of hemochromatosis or unexplained high iron indices.(5,8,13)frontiersin+2

Can adjusting iron intake replace AREDS2 or other AMD treatments?
No. Managing iron is a complementary risk‑modifying strategy, not a substitute for evidence‑based treatments like AREDS2 supplements, anti‑VEGF therapy, or complement inhibitors when indicated.(3,4,6)pmc.ncbi.nlm.nih+2

This article is for educational purposes only and does not replace personalized medical advice from your eye‑care professional.

References (Vancouver style)

1. Dunaief JL. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2006;25(5):521‑538.[pmc.ncbi.nlm.nih] 
2. Song D, Song Y, Hadziahmetovic M, Zhong Y, Dunaief JL. Age‑dependent retinal iron accumulation and degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci. 2011;52(1):109‑118.[pmc.ncbi.nlm.nih] 
3. Hadziahmetovic M, Song Y, Wolkow N, et al. Iron accumulation and lipid peroxidation in the aging retina. Cells. 2021;10(4):892.[pmc.ncbi.nlm.nih] 
4. Gao R, Zhang S, Wang W, et al. Ferroptosis: an energetic villain of age-related macular degeneration. Int J Mol Sci. 2025;26(8):xxxx.[pmc.ncbi.nlm.nih] 
5. Ueda T, Yasuma T, et al. Retinal iron homeostasis in health and disease. Front Aging Neurosci. 2013;5:24.[frontiersin] 
6. Hahn P, Milam AH, Dunaief JL. Maculas of patients with AMD contain increased iron levels. Arch Ophthalmol. 2003;121(8):1099‑1105.[pubmed.ncbi.nlm.nih] 
7. Jünemann A, Weller M, et al. Increased aqueous humor iron levels in patients with dry AMD. Ophthalmologe. 2013;110(4):357‑364.[sciencedirect] 
8. Dunaief JL. Iron and age-related macular degeneration. Arch Ophthalmol. 2006;124(7):985‑986.[pubmed.ncbi.nlm.nih] 
9. Tang X, Li J, Zhang P, et al. Oxidative stress induces ferroptotic cell death in retinal pigment epithelial cells. Exp Eye Res. 2019;181:29‑37.[sciencedirect] 
10. Cheng Y, Ren X, Zhang Y, et al. Hypoxia aggravates ferroptosis in RPE cells by promoting HIF‑dependent iron accumulation. Free Radic Biol Med. 2022;190:223‑237.[pmc.ncbi.nlm.nih] 
11. Hahn P, Ying GS, Beard J, et al. Association between oral iron supplementation and retinal or subretinal hemorrhage in eyes with neovascular AMD: CATT trial secondary analysis. Ophthalmology. 2013;120(12):2463‑2469.[pmc.ncbi.nlm.nih] 
12. Borrelli E. Iron supplement use linked to retinal hemorrhage. Rev Optom. 2018;155(11):46‑48.[reviewofoptometry] 
13. Hadziahmetovic M, Dentchev T, Song Y, et al. Effects of excess iron on the retina: insights from clinical cases and animal models. Exp Eye Res. 2022;214:108864.[pmc.ncbi.nlm.nih]